Welcome Guest | Register / Login

Interleukin-2, a Tale of Two Halves: To Suppress or Augment Suppression, That is the Question

Report Includes:

- An introduction to interleukin-2 (IL-2) and identification of its applications
- Insights into the latest trends and technologies in the IL-2 research and development
- Discussion of strategies adopted by IL-2 developers for the successful treatment of cancer and information on NKTR-214, a Nektar Therapeutics product
- Review of recent VC investment in this zone highlighted by Syncona and Novartis Venture Fund recent CHF35m investment in Anaveon AG, a new Swiss Biotech company spun out from the University of Zuirich which is developing a novel oncologic monoclonal antibody that boosts IL-2 but has an improved side-effect profile
- Detailed description of autoimmune responses and possible ways to augment immune responses so as to improve antitumor activity and reduce off target effect
- An understanding of various conditions which may develop as an off-target effects in the cancer treatment such as metastatic melanoma (MM), renal cell carcinoma (RCC), urothelial cancers (US) relapse remitting multiple sclerosis (RRMS), and Type 1 diabetes (T1D)

Summary

This report will assess the latest developments in the interleukin-2 (IL-2) research and development and explore the novel strategies companies are adopting to augment immune response and avoid off-target effects in a wide range of conditions including metastatic melanoma, renal cell carcinoma, urothelial cancers, relapse remitting multiple sclerosis, type 1 diabetes, as well as prophylaxis post-transplant and allergic conditions.

The report provides an introduction to IL-2, when the target was identified and early commercial applications. It reviews the numerous developmental programs including Nektar Therapeutics pegulated IL-2, bempegaldesleukin (previously known as NKTR-214) in phase 3, ADC Therapeutics Sarl antibody drug conjugate ADCT?301 in phase 2, Roche's fusion protein RO6874281 in phase 2 and Medicenna's superkine MDNA109 and MDNA209 in preclinical research.

The report provides a detailed description of autoimmune responses and possible ways that drug development can augment immune responses so as to improve antitumor activity and reduce off target effect. It discusses the safety and off-target effects associated with approved drugs and the strategies companies have adopted to circumvent these side effect. Finally, the report provides insights of the latest trends and technologies in the IL-2 research and development, including a review of recent collaborations and identifies products and companies to watch.
Single User License: This License type does not allow the report to be Printed.
Corporate User License: This License type does not allow the report to be Printed.
Why http://www.marketreportsonline.com/
Interleukin-2, a Tale of Two Halves: To Suppress or Augment Suppression, That is the Question
Published By :BCC Research
Price
How to Purchase
Purchase reports from our site in few easy clicks. Please follow the description given below to complete your purchase process.
Step 1:
Select the report title of your interest, and Click on Buy Now button next to the Price option.
Step 2:
You will arrive at the Purchase page, where you will be requested to Signup (New User) or Login (Registered User). Please note that in-keeping with the security check on the website, you must submit your full details to avoid any inconvenience arising from incorrectly entered data or counterfeit information.
Step 3:
After SignUp/Login, you will arrive at our Payment Page on Paypal. You will see your Order Summary as well as an option to Choose a way to pay. Select a Payment option from Pay with a Paypal account OR Pay with a Debit or Credit Card. MarketReportOnline accepts Visa, MasterCard, American Express and Discover through Paypal. Fill up the required details in the option of your choice.
Step 4:
Once you follow the required process in Step 3 as mentioned above, you have successfully completed the purchase process.
Step 5:
Once you have successfully completed the purchase process, you will receive a confirmation email. The report will then be emailed to you directly by the publisher, as per our agreement with the publisher. For Orders that are placed after working hours, the delivery of the reports will be made on the next business day. For orders that are placed during weekends, the delivery of the reports will be made on the next 'working' business day. Please note, if you select purchase by invoice, you will receive your report only once the payment has been received. If you have any queries about how to order, please Contact Us.
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy